Biliary cirrhosis is liver scarring caused by long-term damage to the bile ducts, the tiny tubes that carry bile from the liver to the small intestine. When these ducts are injured or destroyed, bile builds up in the liver, triggering inflammation that gradually replaces healthy tissue with scar tissue. The condition comes in two forms: primary, where the immune system attacks the bile ducts without a clear external cause, and secondary, where a known problem like gallstones, surgical injury, or chronic pancreatitis blocks or damages the ducts from the outside.
The primary form is now officially called primary biliary cholangitis (PBC) rather than primary biliary cirrhosis, because most patients are diagnosed before cirrhosis actually develops. The name changed in 2015, but “biliary cirrhosis” remains the term many people search for, and the underlying disease is the same.
What Happens Inside the Liver
In PBC, the immune system mistakes the small bile ducts inside the liver for a threat. Immune cells, particularly macrophages and certain white blood cells, infiltrate the tissue around these ducts and trigger a cycle of inflammation and cell death. The bile duct lining cells are destroyed through a process driven by inflammatory signaling molecules, which recruit even more immune cells into the area. Over time, the ducts disappear entirely, a state called ductopenia.
Without functioning bile ducts, bile has nowhere to go. It pools in the liver, and its components are toxic to surrounding cells. The liver responds to this ongoing injury by producing fibrous scar tissue. In early stages, the scarring is limited to the area around the bile ducts. As the disease progresses over years or decades, the fibrosis spreads and can eventually distort the entire liver architecture, which is when true cirrhosis develops.
Secondary biliary cirrhosis follows a different path but ends in a similar place. A physical obstruction, such as a gallstone lodged in a bile duct, surgical scarring, or a tumor pressing on the duct system, prevents bile from draining. The backup of bile causes the same cascade of inflammation and fibrosis. Treating the underlying obstruction can halt the process, which is the key distinction from the autoimmune form.
Who Gets PBC
PBC overwhelmingly affects women, who account for roughly 9 out of 10 cases. It is most commonly diagnosed between the ages of 40 and 60. The current thinking is that genetically susceptible people encounter an environmental trigger, possibly a chemical exposure or infection, that causes the immune system to begin attacking the bile ducts. Having a first-degree relative with PBC increases your risk, and the disease clusters in certain families, though no single gene is responsible.
Symptoms and How They Progress
Many people with PBC feel nothing at all when the disease is first detected through routine blood work. When symptoms do appear, fatigue dominates. Up to 80% of patients report it, and about 40% describe it as severe, the kind that sleep doesn’t fix and that interferes with daily life. Itching (pruritus) is the second hallmark, affecting 20% to 70% of patients. It can range from mildly annoying to debilitating, often worse at night and on the palms and soles of the feet.
As the disease advances, other signs emerge. Jaundice, the yellowing of skin and eyes, signals that bilirubin is rising because the liver can no longer process it effectively. Dry eyes and dry mouth are common, since PBC frequently overlaps with conditions that affect moisture-producing glands. Some people develop small fat deposits under the skin, especially around the eyes, from changes in cholesterol metabolism.
Vitamin Deficiencies and Bone Loss
Bile is essential for absorbing dietary fat, and when bile flow is impaired, your body struggles to take in fat-soluble vitamins: A, D, E, and K. Vitamin D deficiency is especially common and contributes to osteoporosis, which is already a concern in postmenopausal women who make up most of the PBC population. Vitamin A deficiency can cause thinning hair, dry skin, and night vision problems. Low vitamin K can make you bruise or bleed more easily, since it is necessary for normal blood clotting. These deficiencies are manageable with supplements, but they need to be monitored because the malabsorption is ongoing.
How PBC Is Diagnosed
Diagnosis usually begins when a routine blood test shows elevated alkaline phosphatase, an enzyme that rises when bile flow is impaired. The next step is testing for antimitochondrial antibodies (AMA), which are present in up to 95% of people with PBC. A large meta-analysis found that AMA testing has a pooled sensitivity of 84% and specificity of 98%, meaning a positive result is highly reliable for confirming the diagnosis.
A liver biopsy is not required when you have both cholestatic blood work and a positive AMA result. However, a biopsy can help determine how far the disease has progressed by showing the degree of inflammation and scarring. For the roughly 5% of patients who are AMA-negative, other specific antibodies (anti-sp100 and anti-gp210) can support the diagnosis.
Treatment With Bile Acid Therapy
The cornerstone treatment is ursodeoxycholic acid (UDCA), a naturally occurring bile acid given at a dose of 13 to 15 mg per kilogram of body weight per day. UDCA works by replacing the toxic bile acids that build up in the liver with a gentler form, reducing inflammation and slowing the progression of fibrosis. It is one of the few medications proven to change the long-term course of a liver disease, not just manage symptoms.
In a 10-year study of 297 patients, transplant-free survival was 99.7% at one year, 87% at five years, and 71% at ten years, significantly better than predicted without treatment. Patients whose bilirubin and albumin levels normalized on UDCA had a life expectancy comparable to the general population. Doctors reassess your biochemical response after 6 to 12 months on the medication. If alkaline phosphatase and bilirubin levels drop sufficiently, the treatment is considered effective and is continued indefinitely.
About 30% to 40% of patients do not achieve an adequate biochemical response to UDCA alone. For these people, second-line medications are now available. The FDA has approved several options, including drugs that activate different receptors in the liver to further reduce bile acid production and inflammation. These newer therapies are typically added on top of UDCA rather than replacing it.
Managing Symptoms Day to Day
Fatigue from PBC does not respond to UDCA, and there is no single medication that reliably eliminates it. Many patients find that pacing activities, maintaining a consistent sleep schedule, and moderate exercise help the most. Depression and sleep disruption frequently accompany the fatigue, and treating those can make a meaningful difference.
Itching is typically managed with medications that reduce bile acid circulation or block itch signaling in the brain. For mild cases, antihistamines or cool compresses may be enough. Severe pruritus that does not respond to standard treatments is one of the indications for considering liver transplantation, even before cirrhosis develops, because of its devastating effect on quality of life.
Diet and Nutrition
If the disease has progressed to cirrhosis, nutritional needs shift. Current guidelines recommend 25 to 40 calories per kilogram of dry body weight per day and 1.0 to 1.5 grams of protein per kilogram per day to prevent muscle wasting, which is common in advanced liver disease. If fluid retention (ascites) develops, sodium intake should stay at or below 2,000 mg per day. Protein restriction is only appropriate during acute episodes of confusion related to liver dysfunction, and even then it is temporary, limited to 0.6 to 0.8 grams per kilogram per day until the episode resolves.
In earlier stages, no special diet is required, but maintaining a balanced intake with attention to calcium and vitamin D is sensible given the risk of bone loss. Your doctor will likely check fat-soluble vitamin levels periodically and recommend supplements as needed.
Long-Term Outlook
PBC is a chronic disease, but for most people diagnosed today, it is not a death sentence. Early detection and consistent UDCA therapy have dramatically improved outcomes compared to the pre-treatment era, when median survival after diagnosis was roughly 10 to 15 years. Patients who respond well to UDCA and maintain normal bilirubin levels can expect a normal or near-normal lifespan.
For the minority who progress despite treatment, liver transplantation is highly effective, with excellent long-term survival rates. PBC does recur in the transplanted liver in some cases, but the recurrence is generally mild and slow. The disease tends to move at different speeds in different people, and regular monitoring with blood tests every 3 to 6 months allows your medical team to catch any acceleration early and adjust the treatment plan.